EIKEN CHEMICAL CO., LTD.

Eiken Chemical Co., Ltd. specializes in in vitro diagnostic (IVD) reagents and devices focused on nucleic acid extraction, isolation, and detection. Their portfolio includes sample diluents, calibrators, controls, and loop-mediated isothermal amplification (LAMP) detection kits for infectious diseases like tuberculosis and malaria. They also produce fecal immunochemical test (FIT) reagents and accessories for colorectal cancer screening, as well as automated and portable systems for sample processing.

Eiken Chemical Co., Ltd. is headquartered in Japan, which means its devices must comply with both Japanese regulatory standards and international requirements if marketed globally. Since their products are listed in the EUDAMED database and the FDA’s 510(k) system, they likely follow EU MDR (Medical Device Regulation) and FDA’s premarket notification processes for devices classified under EU Class A, B, C, and US FDA Class II.

Eiken Chemical Co., Ltd.’s devices are registered in EUDAMED (the European Union’s medical device registry) and the FDA’s 510(k) premarket notification system (for the US). These registries ensure transparency and traceability for regulators, healthcare providers, and patients. EUDAMED helps verify compliance with EU MDR, while FDA’s 510(k) system confirms that Class II devices meet safety and effectiveness standards before commercialization in the US.

Eiken’s devices fall under EU Class A, B, and C classifications, depending on their risk level (e.g., low-risk Class A for simple FIT reagents to higher-risk Class C for complex nucleic acid detection systems). In the US, they are classified as FDA Class II, which requires premarket notification (510(k)) to demonstrate substantial equivalence to a predicate device. Classification determines the regulatory pathway, with higher-risk devices requiring stricter validation and post-market surveillance.